Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.55 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.52 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.52 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.52 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.52 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.52 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.52 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.52 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.52 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.52 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265313 | 0.87 | GPR119 (0.56) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL5274325 | 0.87 | GPR119 (0.59) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4494369 | 0.86 | GPR119 (0.55) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4269162 | 0.86 | GPR119 (0.55) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL30150132 | 0.86 | GPR119 (0.55) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL27111222 | 0.86 | GPR119 (0.55) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL31058712 | 0.85 | GPR119 (0.52) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL25113591 | 0.85 | GPR119 (0.54) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL29480780 | 0.85 | GPR119 (0.54) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL15391254 | 0.84 | GPR119 (0.53) | GPR119KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002348-A1 | GLP-1 Receptor Agonist and Use Thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002348-A1 | GLP-1 Receptor Agonist and Use Thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4059929-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2022-09-21 | — | — | EP | disclosed |
| CN-114728940-A | GLP-1 receptor agonists and uses thereof | 日东制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021096284-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | 일동제약(주) | 2021-05-20 | — | — | WO | disclosed |
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| EP-2607362-A1 | Piperidine and piperazine carboxylates as FAAH inhibitors | Astellas Pharma Inc. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | ELILILLY AND COMPANY (US) | 2006-09-21 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002348-A1 | GLP-1 Receptor Agonist and Use Thereof | GLP1R, GIPR, GPR119 | GPR119 3/4885CACNB4 2541/4885CACNA1A 1174/4885 |
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | GPR119 118/4885CACNB4 3411/4885CACNA1A 2911/4885 |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | HTR1A, HTR1F, HTR5A | GPR119 329/4885CACNB4 377/4885CACNA1A 393/4885 |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | GPR119 501/4885CACNB4 1008/4885CACNA1A 468/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | GPR119 2513/4885CACNB4 1327/4885CACNA1A 522/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | GPR119 1/4885CACNB4 1721/4885CACNA1A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.